Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet

Trial Profile

Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs MOR 107 (Primary)
  • Indications Diabetic nephropathies; Fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Lanthio Pharma
  • Most Recent Events

    • 09 Feb 2018 Last checked against ClinicalTrials.gov record.
    • 06 Feb 2018 Status changed from recruiting to discontinued as part 1 was completed successfully and part 2 was not conducted.
    • 03 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top